Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.

Adedoyin OO, Loftin CD.

J Cardiovasc Pharmacol. 2016 Aug;68(2):127-42. doi: 10.1097/FJC.0000000000000395.

2.

Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.

Oestreich JH, Steinhubl SR, Ferraris SP, Loftin CD, Akers WS.

J Thromb Thrombolysis. 2014 Oct;38(3):372-9. doi: 10.1007/s11239-014-1058-5.

PMID:
24510678
3.

β-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice.

Trivedi DB, Loftin CD, Clark J, Myers P, DeGraff LM, Cheng J, Zeldin DC, Langenbach R.

Circ Res. 2013 Apr 26;112(9):1219-29. doi: 10.1161/CIRCRESAHA.112.280399. Epub 2013 Mar 22.

4.

Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice.

Ghoshal S, Loftin CD.

PLoS One. 2012;7(11):e44369. doi: 10.1371/journal.pone.0044369. Epub 2012 Nov 27.

5.

Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype.

Mukherjee K, Gitlin JM, Loftin CD.

J Cardiovasc Pharmacol. 2012 Dec;60(6):520-9. doi: 10.1097/FJC.0b013e318270b968.

PMID:
22967986
6.

Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.

Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL.

Pharm Res. 2011 May;28(5):1211-9. doi: 10.1007/s11095-011-0372-2. Epub 2011 Feb 8.

7.

Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice.

Ghoshal S, Trivedi DB, Graf GA, Loftin CD.

J Biol Chem. 2011 Jan 7;286(1):889-98. doi: 10.1074/jbc.M110.139139. Epub 2010 Oct 20.

8.

Solid-state properties of the cyclooxygenase-1-selective inhibitor, SC-560.

Long S, Theiss KL, Mattei A, Loftin CD, Li T.

AAPS PharmSciTech. 2010 Jun;11(2):485-8. doi: 10.1208/s12249-010-9407-y. Epub 2010 Mar 20. No abstract available.

9.
10.

Cyclo-oxygenase-1-selective inhibitor SC-560.

Long S, Theiss KL, Li T, Loftin CD.

Acta Crystallogr Sect E Struct Rep Online. 2009 Jan 23;65(Pt 2):o360. doi: 10.1107/S1600536809001779.

11.

Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.

Gitlin JM, Loftin CD.

Cardiovasc Res. 2009 Feb 1;81(2):400-7. doi: 10.1093/cvr/cvn286. Epub 2008 Oct 22.

12.

Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice.

Gitlin JM, Trivedi DB, Langenbach R, Loftin CD.

Cardiovasc Res. 2007 Jan 1;73(1):227-36. Epub 2006 Oct 27.

PMID:
17137566
13.

Attenuated cyclooxygenase-2 expression contributes to patent ductus arteriosus in preterm mice.

Trivedi DB, Sugimoto Y, Loftin CD.

Pediatr Res. 2006 Dec;60(6):669-74. Epub 2006 Oct 25.

PMID:
17065565
14.

Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.

King VL, Trivedi DB, Gitlin JM, Loftin CD.

Arterioscler Thromb Vasc Biol. 2006 May;26(5):1137-43. Epub 2006 Mar 2.

PMID:
16514081
15.

Generation of a conditional allele of the mouse prostaglandin EP4 receptor.

Schneider A, Guan Y, Zhang Y, Magnuson MA, Pettepher C, Loftin CD, Langenbach R, Breyer RM, Breyer MD.

Genesis. 2004 Sep;40(1):7-14.

PMID:
15354288
16.

Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2.

Loftin CD, Tiano HF, Langenbach R.

Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:177-85. Review.

PMID:
12432917
17.
18.

Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.

Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R.

Cancer Res. 2002 Jun 15;62(12):3395-401.

19.

Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue.

Kim KS, Baek SJ, Flake GP, Loftin CD, Calvo BF, Eling TE.

Gastroenterology. 2002 May;122(5):1388-98.

PMID:
11984525
20.

Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2.

Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH, Langenbach R.

Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1059-64. Epub 2001 Jan 23.

21.

Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis.

Langenbach R, Loftin CD, Lee C, Tiano H.

Ann N Y Acad Sci. 1999;889:52-61. Review.

PMID:
10668482
22.

Disruption of the mouse cyclooxygenase 1 gene. Characteristics of the mutant and areas of future study.

Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Davis BJ, Lee CA.

Adv Exp Med Biol. 1997;407:87-92.

PMID:
9321936
23.
24.

Relative activities of retrovirally expressed murine prostaglandin synthase-1 and -2 depend on source of arachidonic acid.

Chulada PC, Loftin CD, Winn VD, Young DA, Tiano HF, Eling TE, Langenbach R.

Arch Biochem Biophys. 1996 Jun 15;330(2):301-13.

PMID:
8660660
25.

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O.

Cell. 1995 Nov 3;83(3):483-92.

26.

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O.

Cell. 1995 Nov 3;83(3):473-82.

Supplemental Content

Loading ...
Support Center